<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006268</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068211</org_study_id>
    <secondary_id>NABTT-9903</secondary_id>
    <secondary_id>JHOC-NABTT-9903</secondary_id>
    <secondary_id>NEOPHARM-TS-G1-TI4</secondary_id>
    <secondary_id>NEOPHARM-IL13PEI-001-R03</secondary_id>
    <nct_id>NCT00006268</nct_id>
  </id_info>
  <brief_title>Immunotoxin Therapy in Treating Patients With Malignant Glioma</brief_title>
  <official_title>Interstitial Infusion of IL 13-PE38QQR Cytotoxin in Recurrent Malignant Glioma: Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New Approaches to Brain Tumor Therapy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells.&#xD;
      This may be an effective treatment for malignant glioma.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of immunotoxin therapy in treating&#xD;
      patients who have malignant glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxic effects and maximum tolerated dose (MTD) of interstitial&#xD;
           interleukin-13 PE38QQR immunotoxin in patients with malignant glioma.&#xD;
&#xD;
        -  Determine the response rate, duration of response, time to response, overall survival,&#xD;
           and time to progression in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxic effects of this drug at the MTD in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
      Patients undergo stereotactic biopsy of brain tumor followed by CT guided stereotactic&#xD;
      placement of 2 intratumoral catheters on day 0. Patients with histologically confirmed&#xD;
      malignant glioma receive interleukin-13 PE38QQR immunotoxin interstitially over 96 hours&#xD;
      beginning on day 1. Patients with a residual enhancing mass undergo repeat catheter placement&#xD;
      on day 56 and then receive a second interstitial infusion beginning on day 57 in the absence&#xD;
      of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of interleukin-13 PE38QQR immunotoxin until&#xD;
      the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of&#xD;
      6 patients experience dose-limiting toxicity. Additional patients are treated at the MTD.&#xD;
&#xD;
      Patients are followed every 8 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for phase I of the study within 6&#xD;
      months and a total of 12-35 patients will be accrued for phase II of the study within 10-12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cintredekin besudotox</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isolated perfusion</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven malignant glioma (grade 3 or 4)&#xD;
&#xD;
               -  Anaplastic astrocytoma&#xD;
&#xD;
               -  Glioblastoma multiforme&#xD;
&#xD;
               -  Malignant mixed oligoastrocytoma&#xD;
&#xD;
          -  Must have undergone cranial radiotherapy with tumor dose of at least 48 Gy and at&#xD;
             least 12 weeks prior to study&#xD;
&#xD;
          -  Must have undergone supratentorial brain tumor surgery or biopsy&#xD;
&#xD;
          -  Must have radiographic evidence of recurrent or progressive supratentorial tumor&#xD;
             compared with prior study&#xD;
&#xD;
               -  Must have solid portion measuring 1.0-5.0 cm in maximum diameter&#xD;
&#xD;
               -  Maximum of 1 satellite lesion allowed if separated from the primary mass by less&#xD;
                  than 3 cm&#xD;
&#xD;
               -  No tumor crossing the midline&#xD;
&#xD;
               -  No leptomeningeal tumor dissemination&#xD;
&#xD;
               -  No impending herniation or spinal cord compression&#xD;
&#xD;
          -  No uncontrolled seizures&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  PT and PTT no greater than upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and SGPT no greater than 2.5 times ULN&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated carcinoma in&#xD;
             situ or basal cell skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior intralesional chemotherapy for malignant glioma&#xD;
&#xD;
          -  At least 3 weeks since other prior chemotherapy (6 weeks since prior nitrosoureas) and&#xD;
             recovered&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent corticosteroids allowed, but dose must remain stable or be tapered during&#xD;
             study&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior focal radiotherapy (e.g., any form of stereotactic radiotherapy or&#xD;
             brachytherapy) for malignant glioma&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from any prior therapy&#xD;
&#xD;
          -  No other concurrent investigational agent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Weingart, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute at University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Neurological Disorders and Stroke</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center at the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284-7811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2005</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

